Side effects of Mounjaro injections: what to expect and when to act

The first few weeks: what most people actually experience

Picture this: your first Mounjaro pen arrives. You inject on a Sunday morning, and by Monday you feel vaguely queasy and not especially hungry. That is, by some margin, the most common early experience people describe. The nausea is real, but it is rarely the dramatic kind. Gastric emptying slows when tirzepatide activates the GIP and GLP-1 receptors, and your digestive system takes time to recalibrate.

The side effects seen most consistently across clinical trials and reported in NHS guidance on tirzepatide include nausea, vomiting, diarrhoea, constipation, indigestion or reflux, and excess burping. Fatigue and headache also appear in the data, as do injection-site reactions such as redness or mild bruising where the pen was used. None of these are unusual for a medicine that works through gut-hormone pathways.

The pattern matters as much as the list. Symptoms tend to cluster in the first week after starting or stepping up a dose, then ease. If you are methodical about rotating your injection sites (abdomen, thigh, upper arm, never the same spot twice in a row) injection-site reactions are generally minor. A quick check before each injection that the skin at your chosen site looks normal and is not sore from last time takes under a minute and is worth building into the habit. Guidance on injection technique is covered in the Mounjaro injection guide on this site.

Eating smaller meals, avoiding rich or fatty food in the first days after an injection, and staying well hydrated all reduce how noticeable the digestive effects are. Your prescriber can discuss practical strategies; it is not something you need to manage alone.

Side effects that need prompt medical attention

Most tirzepatide side effects sit in the manageable category. A smaller number do not, and being clear-eyed about them is part of taking the medicine safely.

Pancreatitis is the one that warrants the most attention. In January 2026 the MHRA issued a Drug Safety Update highlighting acute pancreatitis as an infrequent but potentially serious side effect of Mounjaro injection, alongside other reactions that are worth understanding before you start treatment. The symptom to know is severe, persistent stomach pain that radiates toward the back, which may or may not come with vomiting. If you experience that, stop injecting and seek urgent medical care. Do not wait to see whether it settles.

Other situations that warrant prompt attention rather than a wait-and-see approach: signs of a serious allergic reaction (swelling of the face, lips or throat, difficulty breathing, rapid pulse), symptoms of significant dehydration after severe vomiting or diarrhoea (dizziness, very dark urine, inability to keep fluids down), and upper-right abdominal pain with fever or jaundice, which can indicate gallbladder problems. The MHRA has flagged gallbladder conditions as an area to be aware of in people taking medicines in this class.

If you are also being monitored for diabetic eye disease, tell your ophthalmologist you are on tirzepatide. Rapid improvements in blood-sugar control have occasionally been associated with temporary changes in retinopathy, and your team will want to factor that in.

For anything urgent, call 111 or go to A&E. For ongoing concerns, contact the prescriber who approved your treatment. You can also report any suspected side effect to the MHRA via the Yellow Card scheme, which is how the regulator monitors medicine safety in real-world use. Reports from patients directly have influenced regulatory communications on this class of medicine.

A fuller breakdown of the less common side effects listed in the SmPC is available on the Mounjaro side effects page, including the frequency categories used in the product literature.

Who is most likely to notice side effects, and what affects severity

Not everyone has a difficult time. Some people start Mounjaro with barely a twinge of nausea; others find the first fortnight uncomfortable. The clinical trial data published in SURMOUNT-1 in the New England Journal of Medicine showed that gastrointestinal events were the most frequently reported adverse effects, and that they were more common at higher doses, which is part of why the prescribing schedule starts at 2.5mg, a dose chosen for tolerability rather than weight-loss effect, and steps up gradually.

How quickly you titrate makes a real difference. Rushing a dose increase when GI symptoms are still pronounced tends to compound them; your prescriber's role is partly to pace that progression based on how you are actually feeling, not a fixed calendar. Evidence reviews from people who took tirzepatide as part of ongoing clinical programmes consistently show that side effects peak around the transition points and then recede.

Age, previous digestive sensitivities, and whether you have a history of conditions such as gastroparesis can all affect individual experience. The prescriber at our clinical team reviews each person's medical background before prescribing, and that review is repeated at every dose stage, there is no auto-renewal here. If you are curious about how tirzepatide compares with semaglutide in terms of tolerability, the side effects of weight-loss injections page covers both medicines side by side.

The side-effect picture for slimming injections including Mounjaro is not dramatically different from other medicines in the weight-loss injection class, but the dual mechanism means the GI effects can be slightly more pronounced for some people than with semaglutide alone. This is worth knowing in advance, not to discourage anyone, but so that the first queasy morning does not feel like something has gone wrong.

Talking through side effects as part of your consultation at nume

If you are considering Mounjaro through a private route and wondering whether the side-effect profile is something you could manage, that is exactly the conversation our prescribers have during the consultation. They are GPhC-registered Independent Prescribers reviewing each case personally, and side effects, your health background and how to handle the titration schedule are all part of what gets discussed. Nothing is rubber-stamped.

If you want to understand what Mounjaro injections are and how they work before committing to a consultation, that background is worth reading alongside the eligibility criteria below. Mounjaro is a prescription-only medicine licensed in the UK for adults with a BMI of 30 or above, or 27 or above alongside a relevant weight-related condition such as high blood pressure, type 2 diabetes or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance. Suitability depends on the full picture, not the BMI number alone, and certain medical histories, including a personal or family history of medullary thyroid cancer or pancreatitis, require careful prescriber assessment. Pregnancy, breastfeeding and trying to conceive are all situations where Mounjaro is not recommended.

After approval, aftercare from our team is available seven days a week. If a side effect concerns you in week three, you do not have to wait for a scheduled review. The free consultation is the starting point; the conversation continues from there. You can also visit the FAQs page for common questions about what to expect during treatment, or explore a broader overview of weight-loss treatments if you are still weighing your options.